Evidence map›Paper›PMID 42350643›Full record

Trial reportNature medicine2026

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER

Alex De Caluwé, Isabelle Desmoulins, Kim Cao, Vincent Remouchamps, Adinda Baten, Eleonore Longton, Karine Peignaux, Andrea Joaquin Garcia, David Venet, Luca Arecco and 15 more

Abstract readClinical Trial, Phase IIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Alex De CaluwéInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium. alex.decaluwe@bordet.be.ORCID http://orcid.org/0000-0001-5989-7017
Isabelle DesmoulinsCentre Georges-François Leclerc, Université Bourgogne Europe, Dijon, France.
Kim CaoInstitut Curie, Paris, France.ORCID http://orcid.org/0000-0003-2475-1821
Vincent RemouchampsCHU St Elisabeth, Namur, Belgium.
Adinda BatenUniversitaire Ziekenhuizen Leuven, Leuven, Belgium.
Eleonore LongtonHôpital Universitaire St Luc, Brussels, Belgium.
Karine PeignauxCentre Georges-François Leclerc, Université Bourgogne Europe, Dijon, France.
Andrea Joaquin GarciaInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
David VenetInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0001-9038-5271
Luca AreccoInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Elisa AgostinettoInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0003-0295-7511
Guilherme Nader-MartaInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0001-7864-3637
Zoë DenisInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Jennifer DhontInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Paulus KristantoInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0002-1657-5250
Xavier CatteauInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Denis LarsimontInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Roberto SalgadoZAS Hospitals, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1110-3801
Philip PoortmansIridium Netwerk, Antwerp, Belgium.
John StaggGoodman Cancer Institute, McGill University, Montreal, Quebec, Canada.
Christos SotiriouInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0002-5745-9977
Martine PiccartInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Michail IgnatiadisInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0002-4493-3748
Emanuela RomanoInstitut Curie, Paris, France.ORCID http://orcid.org/0000-0002-1574-5545
Laurence BuisseretInstitut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0002-3751-0819

Funding

Stichting Tegen Kanker (Belgian Foundation Against Cancer) 2024-186
6 · The paper itself

Abstract

Patients with estrogen receptor-positive (ER

Indexed as

Antibodies, MonoclonalBreast NeoplasmsRadiosurgeryAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoadjuvant TherapyPathologic Complete ResponseReceptors, EstrogenTumor MicroenvironmentAntibodies, MonoclonaldurvalumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Estrogen

Identifiers

PMID42350643
PMCPMC13375581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.